In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Avrobio (AVRO). The company’s shares closed last Monday at $14.43, close to its 52-week low of $11.85.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 20.5% and a 46.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avrobio with a $31.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.00 and a one-year low of $11.85. Currently, Avrobio has an average volume of 194.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network.
